Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E14.07 EPS (ttm)16.28 Insider Own0.10% Shs Outstand219.05M Perf Week-3.86%
Market Cap50.17B Forward P/E11.37 EPS next Y20.14 Insider Trans-3.90% Shs Float218.43M Perf Month-18.12%
Income3.70B PEG1.80 EPS next Q4.69 Inst Own88.50% Short Float1.01% Perf Quarter-9.03%
Sales10.94B P/S4.59 EPS this Y24.00% Inst Trans-0.76% Short Ratio1.22 Perf Half Y-23.71%
Book/sh47.18 P/B4.85 EPS next Y6.74% ROA19.00% Target Price336.33 Perf Year-44.32%
Cash/sh16.37 P/C13.99 EPS next 5Y7.80% ROE34.50% 52W Range232.16 - 417.68 Perf YTD-25.24%
Dividend- P/FCF15.32 EPS past 5Y31.30% ROI23.50% 52W High-45.17% Beta0.97
Dividend %- Quick Ratio2.20 Sales past 5Y17.90% Gross Margin88.70% 52W Low-1.35% ATR6.79
Employees7350 Current Ratio2.60 Sales Q/Q6.70% Oper. Margin47.10% RSI (14)28.45 Volatility2.32% 2.26%
OptionableYes Debt/Eq0.63 EPS Q/Q26.80% Profit Margin33.80% Rel Volume1.51 Prev Close238.62
ShortableYes LT Debt/Eq0.63 EarningsJul 21 BMO Payout0.00% Avg Volume1.80M Price229.02
Recom2.10 SMA20-11.30% SMA50-13.81% SMA200-16.79% Volume2,639,800 Change-4.02%
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Jun-25-16 02:00PM  Think of This Stock as Buy-ogen
Jun-24-16 02:41PM  2 Biotech Stocks That Won't Pay a Dividend Anytime Soon, and 1 That Should at Motley Fool
01:53PM  Biotech: Buy the Brexit Blowup? at Barrons.com
09:56AM  Brexit means little for biotech stocks, analyst says at MarketWatch
Jun-23-16 06:56PM  The Largest and Most Absurd Stock Buybacks
04:39PM  Better Buy: Biogen Inc. vs. Celgene Corporation at Motley Fool
Jun-22-16 07:01PM  Cramer: Why Can't We Get Together on Mergers?
04:57PM  Medicare 'Death Panel' Is On Ice; Biotechs Rally
04:04PM  Verifone, Biogen Crash Wednesdays 52-Week Low Club at 24/7 Wall St.
10:50AM  Biotech: Why Take the Risk? at Barrons.com
Jun-21-16 05:40PM  Why Biogen Inc. Is Down 22.5% In 2016 at Motley Fool
04:43PM  Why Biotech is Getting Crushed at Barrons.com
04:19PM  BIOGEN INC. Files SEC form 8-K, Change in Directors or Principal Officers
02:07PM  Biotech ETFs Reeling in Longest Sector Selloff in Two Decades
11:00AM  Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology Business Wire
08:03AM  These 5 Biotech Stocks Are Ridiculously Cheap at Motley Fool
Jun-20-16 04:01PM  Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016 Business Wire
Jun-17-16 12:42PM  Stock Sector Count Can Identify Pockets Of Strength
07:00AM  Biogen Remains Undervalued at Morningstar
Jun-16-16 10:10AM  Stock Market News for June 16, 2016
08:04AM  Why Now Is the Time to Buy Shares of Biogen
Jun-13-16 11:36AM  The Neglected Biogen
09:30AM  The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Jun-12-16 05:25PM  Insiders See Huge Upside In These Biotechs
02:35PM  Biogen And Gilead Sciences Buck Biotech Short Interest Trend
11:01AM  Is Biogen a Buy After its Clinical Failure? at Motley Fool
Jun-10-16 06:42PM  5 Appealing Biotechnology Stocks for Healthy Long-term Returns
03:42PM  Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure at Motley Fool
01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
11:03AM  What if Biogen Loses its Bet on More Pipeline Projects?
08:10AM  Short Sellers Become More Selective on Major Biotechs at 24/7 Wall St.
Jun-09-16 04:26PM  BIOGEN INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
02:21PM  Better Buy: Anavex Life Sciences Corp. vs. Biogen at Motley Fool
01:40PM  Biogen, Inc. Value Analysis (NASDAQ:BIIB) : June 9, 2016
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
07:08AM  New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogens Anti-TNF Biosimilars Portfolio Business Wire
Jun-08-16 04:31PM  Citigroup Downgrades Shares of Biogen at TheStreet
03:33PM  There's a new most-valuable public company in the Bay State until August at bizjournals.com
03:13PM  Moody's: Biogen's anti-lingo study failure is credit negative at Moody's
02:59PM  Why Biogens Stock Price Has Fallen
02:38PM  Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
01:46PM  Trending tickers: PAY, PLAY, SKUL, BIIB
11:33AM  Biotech Stocks: Wait Until Next Year at Barrons.com
11:13AM  Biogen's Playing Too Much Lotto at Bloomberg
10:52AM  Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
08:25AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : June 8, 2016
08:05AM  Analysts' Actions -- Anadarko, Biogen, VeriFone, Ralph Lauren and More
07:00AM  Trader's Daily Notebook: Gusher for Oil Stocks
01:53AM  [$$] Biogen Shares Down as Multiple Sclerosis Therapy Misses Study Goals at The Wall Street Journal
Jun-07-16 08:54PM  [$$] Biogen Shares Down as Multiple Sclerosis Therapy Misses Study Goals at The Wall Street Journal -12.76%
05:57PM  Why Biogen, LendingClub, and Valeant Pharmaceuticals Slumped Today at Motley Fool
05:40PM  These Drug Stocks Just Disappointed Investors -- Are They Buys? at Motley Fool
05:08PM  Biogen CIO Matt Griffiths No Longer With Company at The Wall Street Journal
04:54PM  Biogen Loses Big MS Gamble As Anti-LINGO Fails Clinical Trial
04:27PM  [$$] Biogen falls after clinical trial setback at Financial Times
04:11PM  S&P 500 Closes at 2016 High as Crude Tops $50
04:04PM  Why is Biogen (BIIB) Stock Plunging Today?
03:59PM  Here's Why Shares of Biogen and Alexion Tanked On Tuesday at TheStreet
03:39PM  US STOCKS-S&P edges closer to record high; energy shares lead
02:27PM  [$$] Biogen Selloff Makes for Great Buying Opportunity at Barrons.com
02:03PM  Biotech Smacked Despite Broad U.S. Stock Rally at Barrons.com
01:30PM  Why Biogen Inc's Shares Couldn't Find SYNERGY Today at Motley Fool
01:01PM  S&P 500 Flirts With All-Time High; Biotechs Weigh On Nasdaq
12:37PM  Trending Tickers: Z, VRX, BIIB, ALXN
12:30PM  Biogen Is Going Down a Rabbit Hole of Mediocrity and Uncertainty
12:13PM  Biotech stocks on the move
12:05PM  Alexion Pharmaceuticals: Time to Buy? at Barrons.com
12:03PM  Instant Analysis: Biogen's Anti-Lingo-1 Flunks Game-Changing Study In MS at Motley Fool
11:40AM  Biogen: 'Major Upside Opportunity Gone' at Barrons.com
11:27AM  Stocks Rise Even As Biotechs Sicken, Ralph Lauren Chapped
11:19AM  Biogen loses $8B in market value after drug fails mid-stage trial at bizjournals.com
11:13AM  Valeant Pharmaceuticals tumbles; Ralph Lauren job cuts; Zillow to pay $130M to settle lawsuit
10:55AM  Chips Power Up But Health ETFs Get A Drubbing On Slew Of Bad News
10:52AM  Biogen's MS drug fails to meet goals in study
10:36AM  Tuesdays Headline Makers: Ralph Lauren, Axiall, Godaddy, More at Insider Monkey
08:55AM  Why Biogen (BIIB) Stock Is Tanking Today
08:14AM  Biogen Plunges as Multiple Sclerosis Drug Fails in Trial at Bloomberg
07:59AM  Biogen's MS drug misses main goal in mid-stage study
07:43AM  Biogen's stock tumbles after drug study fails to meet endpoints at MarketWatch
07:30AM  Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis Business Wire
Jun-06-16 01:20PM  Relypsa: Largest Institutional Shareholders are Buying More Stock
Jun-05-16 12:42PM  5 Trade Ideas for Monday: Agrium, Biogen, Bristol-Myers, Bloomin' Brands and Canadian National Railway
07:21AM  Forget Biogen: These 3 Stocks Are Better Buys at Motley Fool
Jun-04-16 11:41AM  The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit) at Motley Fool
Jun-03-16 03:05PM  3 Reasons AbbVie's and Biogen's Latest MS Drug Might Flop at Motley Fool
02:18PM  Biotech: What's the Trade? at Barrons.com
11:02AM  Pfizer, Sanofi Could Eye Biogen's Hemophilia Franchise
Jun-02-16 05:55PM  Kite (KITE) and Biogen's Drugs Included in PRIME Initiative
03:07PM  Why does Biogen need a sixth drug for multiple sclerosis? at bizjournals.com
10:23AM  Biotech Stocks: Don't Expect a 'Miraculous Recovery' at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Jun-01-16 02:40PM  Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
02:32PM  Biogen Says EU Medicines Agency Accepted Its Investigational Alzheimer's Disease Treatment Aducanumab
11:45AM  Biogens Investigational Alzheimers Disease Treatment Aducanumab Accepted into European Medicines Agencys PRIME Program Business Wire
May-31-16 06:46PM  How to Discover the Best Biotechs in the World
10:10AM  Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS
09:25AM  FDA Approves Biogen and AbbVie's MS Treatment at Investopedia
07:30AM  Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy Business Wire
May-30-16 09:22AM  Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod
02:05AM  FLIXABI®, Biogens Infliximab Biosimilar Referencing Remicade®, Approved in the European Union Business Wire
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM